This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
SparkCures ID | 1117 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 13 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Note: Subject must not be a candidate for regimens known to provide clinical benefit.
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Cerecor, Inc. to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors